Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Clinical trial NCT04268277 · TERMINATED

Trial details

NCT number: NCT04268277
Sponsor: University of Ulm
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Marginal Zone Lymphoma

Start date: 2022-03-01
Primary completion: 2024-12-06
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.